7 Firms Guide GSK Spin-Off Haleon In London Listing
Haleon PLC debuted Monday as a standalone company worth £30.5 billion ($36.4 billion) on the London Stock Exchange after completing its de-merger from the U.K. drugmaker GlaxoSmithKline PLC....To view the full article, register now.
Already a subscriber? Click here to view full article